MedPath

Bevacizumab

Generic Name
Bevacizumab
Brand Names
Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
Drug Type
Biotech
CAS Number
216974-75-3
Unique Ingredient Identifier
2S9ZZM9Q9V

Overview

There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies. In 2004, bevacizumab (Avastin) gained FDA approval for specific types of cancer, and became the first antiangiogenic agent introduced to the market. It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A. Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity, and stage of cancer. Bevacizumab was approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021. There are also biosimilars of bevacizumab available, such as bevacizumab-awwb, bevacizumab-maly, and bevacizumab-adcd. Interestingly, researchers have identified higher VEGF expression in patients with COVID-19, which may contribute to lung pathologies including acute respiratory syndrome (ARDS) and acute lung injury (ALI). As such, bevacizumab is being investigated for the treatment of lung complications associated with severe cases of COVID-19.

Background

There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies. In 2004, bevacizumab (Avastin) gained FDA approval for specific types of cancer, and became the first antiangiogenic agent introduced to the market. It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A. Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity, and stage of cancer. Bevacizumab was approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021. There are also biosimilars of bevacizumab available, such as bevacizumab-awwb, bevacizumab-maly, and bevacizumab-adcd. Interestingly, researchers have identified higher VEGF expression in patients with COVID-19, which may contribute to lung pathologies including acute respiratory syndrome (ARDS) and acute lung injury (ALI). As such, bevacizumab is being investigated for the treatment of lung complications associated with severe cases of COVID-19.

Indication

As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer; epithelial ovarian cancer; fallopian tube cancer; breast cancer; and recurrent glioblastoma. Interestingly, bevacizumab is currently under investigation for the treatment of COVID-19 complications including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

Associated Conditions

  • Metastatic Breast Cancer
  • Metastatic Cervical Cancer
  • Metastatic Colorectal Cancer (CRC)
  • Metastatic Non-squamous Non Small Cell Lung Cancer
  • Metastatic Renal Cell Carcinoma ( mRCC)
  • Persistent Cervical Cancer
  • Recurrent Cervical Cancer
  • Recurrent Glioblastoma
  • Relapsed Glioblastoma
  • Stage III Fallopian Tube Cancer
  • Stage III Ovarian Epithelial Cancer
  • Stage III Primary Peritoneal Cancer
  • Stage IV Fallopian Tube Cancer
  • Stage IV Ovarian Epithelial Cancer
  • Stage IV Primary Peritoneal Cancer
  • Locally advanced nonsquamous non-small cell lung cancer
  • Recurrent Non-Squamous Non-Small Cell Lung Cancer
  • Recurrent Platinum-Sensitive Epithelial Ovarian Cancer
  • Recurrent Platinum-resistant Epithelial Ovarian Cancer
  • Recurrent platinum drug resistant Fallopian tube cancer
  • Recurrent platinum drug resistant primary peritoneal cancer
  • Recurrent platinum sensitive primary peritoneal cancer
  • Recurrent platinum-sensitive fallopian tube cancer
  • Unresectable Non-Squamous Non-Small Cell Lung Cancer
  • Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Research Report

Published: Jul 7, 2025

Bevacizumab (DB00112): A Comprehensive Monograph on its Pharmacology, Clinical Efficacy, and Evolving Therapeutic Landscape

Section 1: Introduction to Bevacizumab: A First-in-Class Anti-Angiogenic Agent

1.1 Developmental History and Regulatory Milestones

Bevacizumab, marketed under the brand name Avastin® and its biosimilars, represents a landmark achievement in oncology, being the first anti-angiogenic agent to gain regulatory approval and enter the clinical armamentarium.[1] Its development was founded upon the pivotal discovery that tumor growth is an angiogenesis-dependent process. The scientific rationale posits that by inhibiting the formation of new blood vessels, a tumor's supply of oxygen and nutrients can be restricted, thereby arresting its growth and metastatic potential.[1] This therapeutic strategy targets a fundamental process of tumorigenesis rather than the cancer cells themselves.

The agent achieved its first major regulatory milestone on February 26, 2004, when the U.S. Food and Drug Administration (FDA) granted approval for its use in combination with chemotherapy for the first-line treatment of metastatic colorectal cancer (mCRC).[4] This approval heralded a new era of targeted therapy in oncology. Subsequently, bevacizumab received marketing authorisation from the European Medicines Agency (EMA) on January 12, 2005, and from Health Canada on March 24, 2010, solidifying its role as a global standard of care for various malignancies.[6] The drug's development was driven by a wealth of evidence indicating that vascular endothelial growth factor (VEGF), specifically VEGF-A, is a critical mediator of angiogenesis, lymphangiogenesis, and tumor proliferation, making it an exceptionally attractive therapeutic target.[1]

1.2 Biochemical Profile: A Humanized IgG1 Monoclonal Antibody

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/07/08
Not Applicable
Not yet recruiting
2025/06/17
Phase 2
Not yet recruiting
2025/06/17
Phase 3
Not yet recruiting
2025/06/15
Phase 2
Not yet recruiting
Sun Yat-sen University
2025/06/10
Phase 4
Active, not recruiting
Kasr El Aini Hospital
2025/06/10
Phase 1
Recruiting
Sun Yat-sen University
2025/06/10
Phase 2
Not yet recruiting
2025/06/09
Phase 2
Not yet recruiting
2025/06/06
Phase 2
Not yet recruiting
Wuhan Union Hospital, China
2025/06/06
Phase 2
Not yet recruiting
Qianfoshan Hospital

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Genentech, Inc.
50242-060
INTRAVENOUS
100 mg in 4 mL
9/23/2022
Amgen Inc
55513-207
INTRAVENOUS
400 mg in 16 mL
11/18/2021
CELLTRION USA, Inc.
72606-012
INTRAVENOUS
400 mg in 16 mL
2/22/2023
Genentech, Inc.
50242-061
INTRAVENOUS
400 mg in 16 mL
9/23/2022
Amneal Pharmaceuticals LLC
70121-1755
INTRAVENOUS
400 mg in 16 mL
4/23/2022
Amgen Inc
55513-206
INTRAVENOUS
100 mg in 4 mL
11/18/2021
CELLTRION USA, Inc.
72606-011
INTRAVENOUS
100 mg in 4 mL
2/22/2023
Pfizer Laboratories Div Pfizer Inc
0069-0315
INTRAVENOUS
100 mg in 4 mL
2/24/2023
Pfizer Laboratories Div Pfizer Inc
0069-0342
INTRAVENOUS
400 mg in 16 mL
2/24/2023
Amneal Pharmaceuticals LLC
70121-1754
INTRAVENOUS
100 mg in 4 mL
4/23/2022

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
ZIRABEV CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/4 ML
SIN16286P
INFUSION, SOLUTION CONCENTRATE
100 mg/vial
7/26/2021
MVASI CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML
SIN16151P
INFUSION, SOLUTION CONCENTRATE
25 mg/mL
4/10/2021
Avastin Concentrate for Solution for Infusion 100mg/4ml
SIN13065P
INFUSION, SOLUTION CONCENTRATE
25mg
3/16/2005
ABEVMY™ CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML
SIN16583P
INJECTION, SOLUTION, CONCENTRATE
25 mg/ml
8/29/2022
ZIRABEV CONCENTRATE FOR SOLUTION FOR INFUSION 400 MG/16 ML
SIN16287P
INFUSION, SOLUTION CONCENTRATE
400 mg/vial
7/26/2021
Avastin Concentrate for Solution for Infusion 400mg/16ml
SIN14097P
INFUSION, SOLUTION CONCENTRATE
400mg
2/6/2012
VEGZELMA CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML
SIN16810P
INFUSION, SOLUTION CONCENTRATE
25 mg/ml
6/16/2023
AVAMAB Concentrate for Solution for Infusion 100mg/4mL
SIN17101P
INFUSION, SOLUTION CONCENTRATE
100mg/4ml
9/25/2024
AVAMAB Concentrate for Solution for Infusion 400mg/16mL
SIN17102P
INFUSION, SOLUTION CONCENTRATE
400mg/16ml
9/25/2024

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Bevacizumab Injection
国药准字S20250004
生物制品
注射剂
1/8/2025
Bevacizumab Injection
国药准字S20240051
生物制品
注射剂
11/15/2024
Bevacizumab Injection
国药准字S20210047
生物制品
注射剂
11/24/2021
Bevacizumab Injection
国药准字SJ20170035
生物制品
注射剂
4/22/2022
Bevacizumab Injection
国药准字S20210044
生物制品
注射剂
11/17/2021
Bevacizumab Injection
国药准字S20210020
生物制品
注射剂
6/22/2021
Bevacizumab Injection
国药准字S20233105
生物制品
注射剂
2/28/2023
Bevacizumab Injection
国药准字S20210049
生物制品
注射剂
11/30/2021
Bevacizumab Injection
国药准字S20200013
生物制品
注射剂
5/6/2023
Bevacizumab Injection
国药准字S20210048
生物制品
注射剂
11/30/2021
© Copyright 2025. All Rights Reserved by MedPath